johnson_and_johnson_jj

Germany demands that J&J replace contaminated vaccine doses

June 14, 2021
Sales and Marketing

Germany’s health ministry has demanded that J&J must deliver 6.5 million COVID-19 vaccine doses to Germany in July to make …

Third FDA panel member quits over controversial Alzheimer’s drug approval

June 11, 2021
Medical Communications

The third FDA advisory panel member has quit over the approval of a controversial new Alzheimer’s drug. Biogen’s drug, aducanumab, …

“The future of pain care”: Virtual reality therapy proven to aid chronic pain

June 11, 2021
Medical Communications CBT, Virtual reality, chronic pain management, technology

A novel digital therapeutics software, DTxP, has shown statistically significant benefits for patients with chronic low back pain (CLBP) in …

G7: UK to donate 100 million surplus vaccine doses

June 11, 2021
Medical Communications Boris Johnson, COVID-19, G7, Joe Biden, UK, US, Vaccine

Boris Johnson has announced at the G7 meeting in Cornwall that the UK will donate over 100 million surplus doses …

sanofi_hq__boetie_hall_web

Sutimlimab meets primary endpoint in treating cold agglutinin disease

June 11, 2021
Medical Communications

A Phase III study evaluating the safety and efficacy of sutimlimab in people with cold agglutinin disease (CAD) met its …

top_10_image_2_9

Pharmafile.com’s top 10 news stories of the week

June 11, 2021
Medical Communications

Among our ten most-read stories this week: AstraZeneca vs GSK: Cancer drug court battle could cost hundreds of millions; New …

Phase III breast cancer trial meets primary endpoint

June 10, 2021

Byondis has revealed positive Phase III results for (ADC) [vic-]trastuzumab duocarmazine (SYD985) in patients with HER2-positive unresectable locally advanced or …

covid_cell_1_20

Pharmafile.com’s weekly COVID-19 news round-up

June 10, 2021

The past week has seen lots of vaccine-related news, Pfizer-BioNTech has expanded its COVID-19 vaccine study in children under 12, …

NICE release new guidance on rheumatoid arthritis treatment

June 10, 2021
NICE, biosimilar, rheumatoid arthritis

NICE has today published final draft guidance for the treatment of moderate rheumatoid arthritis in patients who have not responded …

nhs_sign

SMC approves nintedanib for patients with chronic lung disease

June 10, 2021

The Scottish Medicines Consortium (SMC) has approved nintedanib for NHSScotland for the treatment of adult patients with chronic fibrosing interstitial …

0000

COVID chaos: Survey reveals global oncology trial disruptions

June 10, 2021
data, oncology

The pandemic has had a widespread impact across the healthcare industry and the world, however, a recent global survey from …

picture1

Pfizer to expand COVID vaccine study in children under 12

June 10, 2021
COVID-19, Pfizer, Vaccine

Pfizer has announced that it will begin large-scale testing of its COVID-19 vaccine after selecting a lower dose of the …

Phase III trial supports the potential use of Cabometyx for thyroid cancer

June 8, 2021
Manufacturing and Production

Ipsen and Exelixis have announced detailed results from the Phase III COSMIC-311 pivotal trial of Cabozantinib in patients with previously …

hand-3666974_1280

FDA approves first new Alzheimer’s drug in two decades

June 8, 2021
Manufacturing and Production

Biogen’s controversial new drug, aducanumab, has been accepted by the FDA, making it the first Alzheimer’s drug to be approved …

img_4190-e1376666350337-web

MHRA approves venetoclax as acute myeloid leukemia treatment

June 8, 2021
Manufacturing and Production EC, EU, MHRA, leukemia

The MHRA has announced its approval for AbbVie’s venetoclax, in combination with a hypomethylating agent, for the treatment of newly …

merckwindow_web

MSD announce new data from advanced renal cell carcinoma trial

June 8, 2021
Manufacturing and Production MSD, rcc

Merk (MSD) has announced positive data from its Phase III Clear/Keynote-581 trial on Keytruda (pembrolizumab) plus Lenvima (lenvatinib), and Lenvima …

New NICE recommendation for Astellas prostate cancer drug

June 8, 2021
Manufacturing and Production Astellas, NICE, prostate cancer

A newly published Final Appraisal Determination by NICE has recommended Astellas’ Xtandi (enzalutamide) plus androgen deprivation therapy (ADT), as an …

Astronomy & cancer: Researchers join forces to study CUP

June 7, 2021
Sales and Marketing oncology

Astronomers from Durham University have joined forces with cancer researchers to advance the diagnosis and treatment of cancer of unknown …

UK vaccination update

June 7, 2021
Sales and Marketing

With 21 June fast approaching, and the Delta variant rising in the UK, here’s the latest vaccine update. Firstly, the …

AstraZeneca vs GSK: Cancer drug court battle could cost hundreds of millions

June 7, 2021
Sales and Marketing AstraZeneca, GSK, court

AstraZeneca has launched a court case against Glaxo Smith Kline (GSK), in a claim that could reach hundreds of millions …

The Gateway to Local Adoption Series

Latest content